FDA’s Predictive Toxicology Roadmap: Implications and Opportunities for Stakeholders - Drug Information Update

Register for FDA’s May 10 Grand Rounds and find out about...

FDA’s Predictive Toxicology Roadmap: Implications and Opportunities for Stakeholders

Thursday, May 10, 2018

 

12:00 p.m. ‒ 1:00 p.m. EST

 

Register here for the webcast

 

Presented by:

 

Suzanne Fitzpatrick, PhD, DABT, ERT 

Senior Advisor for Toxicology

FDA’s Center for Food Safety and Applied Nutrition (CFSAN)

Toxicology is critical to FDA’s mission because it is applied across the breadth of FDA-regulated product areas. Today’s advances in systems biology, stem cells, engineered tissues, and mathematical modeling are offering exciting opportunities to improve toxicology’s predictive ability--potentially enhancing FDA’s ability to quickly and more accurately predict potential toxicities--and reduce associated risks to the public. And these breakthroughs also hold the potential for replacing, reducing, and/or refining animal testing. 

 

FDA senior toxicologist Dr. Suzanne Fitzpatrick will discuss FDA’s Predictive Toxicology Roadmap, a six-part framework for integrating new predictive toxicology methods into safety and risk assessments of FDA products. She’ll detail FDA’s collaborative efforts to advance toxicology toward a more predictive science with NIH, EPA and other federal agencies through programs like Tox21 and ICCVAM. FDA’s unprecedented role in the development and evaluation of the organs-on-a-chip technology with sister federal agencies and industry will be described and offered as an example of how FDA is enabling innovation in this exciting field.

 

Importantly, Dr. Fitzpatrick will discuss how diverse stakeholders can work with FDA to share ideas, discuss new technologies, and highlight collaborations that are developing and testing new methods.